Insights

Roswell and CC collaborated to develop the world’s first molecular electronics chip for healthcare diagnostics. Roswell has ‘digitised biology’ enabling a sample to be placed on a chip that can run multiple tests, transforming the diagnostics industry from one-test-one-result to one-test-many-results.

A meeting of minds - AI meets biology. This is the conversation that is bridging the gap between bioprocessing and machine learning.

Fresh from the Festival of Genomics and Biodata, our Head of Life Sciences Symon Cotton reflected on the future of the genomics ecosystem. Here he discusses how genomics – plus the emergence of panomics and long read sequencing – could inform clinical practice and patient care… 

The world of DNA testing is changing fast and the race is on to provide cheap, quick genetic diagnoses for patients. So what are the opportunities for companies working in this dynamic field?

Asia’s medical technology market is predicted to account for a third of global medical technology sales by 2025. As such, it's a hotbed for start-ups, so here are our six innovative start-ups to watch that are part of this year’s MedTech Innovator cohort. 

Cell4D is developing ‘fingerprinting’ technology for live cells using mechanomics, a discipline sitting at the intersection of biology and biomechanics. It is a biomarker that Cell4D is using to screen and sort live cells

Founders of early-stage start-ups are characteristically passionate, driven and optimistic. Understandably so. Very often they are nurturing a breakthrough idea with the capacity to disrupt business and change the world for the better. So, as they embark on the mission to sell their vision, they should accentuate the positive and keep negative thoughts of risk to the back of their mind, right? Wrong. 

Yan Lin Lye and a team from CC are embarking on a sequence of mentoring sessions as part of our commitment to MedTech Innovator Asia Pacific. For the second consecutive year, we're collaborating with the organisation to provide hands-on professional support to selected start-up participants.

Access to advanced cell and gene therapies has been limited by their high cost. We've been looking at how AI can play a role in reducing the cost of manufacture of cell and gene therapies and hence make these treatments available to more patients.